Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.42 |
| ▸ | PGR | P06401 | 5/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1291367 | 0.87 | AR (0.43) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1291363 | 0.87 | AR (0.43) | ARPGRNR3C2NR3C1 | |
| SCHEMBL10082762 | 0.84 | CXCR1 (0.33) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1291549 | 0.83 | AR (0.47) | ARPGR | |
| SCHEMBL1291552 | 0.83 | AR (0.47) | ARPGR | |
| SCHEMBL1709976 | 0.80 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1291444 | 0.80 | AR (0.49) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1364976 | 0.80 | AR (0.42) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1364971 | 0.80 | AR (0.42) | ARPGRNR3C2NR3C1 | |
| SCHEMBL1364779 | 0.78 | ALDH1A1 (0.39) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9133182-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2621901-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2621901-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2012047617-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, GPR119 | AR 1/4885PGR 19/4885NR3C2 21/4885 |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | AR 1/4885PGR 19/4885NR3C2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.